论文部分内容阅读
目的 :探讨芪丹通脉片 (QDTMT)对犬心肌耗氧量的影响 .方法 :将实验犬随机分为空白对照组 (Control)、QDTMT大剂量组 (QDTMTH)、QDTMT小剂量组 (QDTMTL)及阳性对照组 (Diltiazem) .用血氧测定仪测定冠状动、静脉血氧含量 ,计算心肌耗氧量 ,氧利用率 .结果 :给药 6 0min后 ,QDTMTH动脉血氧含量降低 ,与Control相比有显著性差异 [(12 4 .2± 2 5 .4)vs (96 8± 4 0 ) ,(137.1± 15 .1)vs (99.9± 2 .4 )和 (137.4±12 .6 )vs (94 3± 2 8)g·L-1,P <0 .0 1].给药 4 5min后 ,QDTMTL心肌耗氧量显著低于Control [(74 .5± 14 )vs (94 .6±11.5 ) ,(76 .0± 17.3)vs(90 .6± 11.5 ) ,(76 .9± 10 .4 )vs (90 .6± 5 .5 )和 (74 .6± 16 .7)vs (95 .0± 4 .9)mL·min-1,P <0 .0 5 ].QDTMTH、QDTMTL的心肌氧利用率均下降 ;6 0min后 ,与Con trol相比有显著性差异 [(84 .9± 8.0 )vs (98.0± 6 .6 ) ,(84 .6±6 .3)vs (94 .6± 4 .3)和 (82 .4± 7.5 )vs (99.9± 6 .6 ) % ,P <0 .0 5 ].结论 :QDTMT可通过降低心肌耗氧量 ,降低氧利用率 ,改善心肌缺血 .
Objective: To investigate the effects of QDTMT on myocardial oxygen consumption in dogs. Methods: The experimental dogs were randomly divided into control group, QDTMT high dose group (QDTMTH), and QDTMT low dose group (QDTMTL). And positive control group (Diltiazem). Determination of oxygen content in coronal artery and venous blood with oxygen analyzer, calculation of myocardial oxygen consumption, oxygen utilization rate. Result: QDTMTH arterial blood oxygen content decreased after 60 minutes of administration, compared with Control phase. There was a significant difference between [(12 4 .2 ± 2 5 .4) vs (96 8 ± 4 0), (137.1 ± 15 .1) vs (99.9 ± 2. 4), and (137.4 ± 12 .6) vs. (94 3 ± 2 8) g · L -1, P <0.01. After administration for 45 minutes, the myocardial oxygen consumption of QDTMTL was significantly lower than that of Control [(74.5±14) vs (94.6%). 11.5), (76.0 ± 17.3) vs (90.6 ± 11.5), (76.9 ± 10.4) vs (90.6 ± 5.5) and (74.6 ± 16.7) vs ( The myocardial oxygen utilization rate of 95.0±4 .9) mL·min-1, P <0.05, QDTMTH, and QDTMTL all decreased; after 60 min, there was a significant difference compared with Con trol [(84. 9 ± 8.0 ) vs (98.0 ± 6.6), (84. 6 ± 6.3) vs (94. 6 ± 4.3) and (82. 4 ± 7.5) vs (99.9 ± 6.6) %. P <0 .0 5 ]. Conclusion: QDTMT can reduce myocardial oxygen consumption by reducing Oxygen utilization, improve myocardial ischemia.